Entresto 50 mg – 28 Tablets

Entresto is a prescription medication used to treat heart failure. It contains two active ingredients: Sacubitril and Valsartan.

Sacubitril works by inhibiting the enzyme Neprilysin, helping to dilate blood vessels and increase the elimination of excess sodium and water. Valsartan blocks the effects of angiotensin II, helping to lower blood pressure and reduce the workload on the heart.

Each Entresto 50 mg tablet contains 24 mg of Sacubitril and 26 mg of Valsartan.

Indications

• Treatment of symptomatic chronic heart failure in adults, particularly heart failure with reduced ejection fraction (HFrEF).

• Reduction of the risk of cardiovascular death in eligible patients with heart failure.

• Reduction of the likelihood of hospitalization due to worsening heart failure.

• Helps improve heart failure symptoms, such as shortness of breath and fatigue, by reducing the workload on the heart.

• May be used in certain cases of heart failure in children aged one year and older, according to medical evaluation and locally approved guidelines.

Dosage and Administration

• Usual dosage for this strength: One Entresto 50 mg tablet twice daily when the physician determines that this is the appropriate starting strength.

• The physician may initiate treatment with the 50 mg strength in certain patients, including those who have not previously received ACE inhibitors or angiotensin receptor blockers (ARBs), or those with severe kidney impairment.

• The dosage may be gradually increased every 2–4 weeks according to the patient’s response and tolerance until the target dose is reached.

• Tablets may be taken with or without food and should be swallowed whole with water.

• Each package contains 28 tablets, providing a 14-day supply when taking one tablet twice daily.

• Follow the prescribed dosage and do not make adjustments without consulting a physician.

Warnings and Precautions

• Contraindicated during pregnancy, as it may cause serious harm to the developing fetus.

• Must not be used simultaneously with angiotensin-converting enzyme (ACE) inhibitors. A minimum interval of 36 hours is required when switching between these treatments.

• Contraindicated in patients with a history of angioedema associated with ACE inhibitors or ARBs.

• May cause severe hypotension, particularly in dehydrated patients or those taking diuretics.

• Kidney function and blood potassium levels should be monitored during treatment.

• Use with caution in patients with kidney impairment or liver dysfunction.

• Avoid combining Entresto with other medications containing Valsartan or other ARBs.

• Consult a physician before using potassium supplements or potassium-containing salt substitutes.

• Must not be used with Aliskiren in patients with diabetes or certain degrees of kidney impairment.

• Breastfeeding is not recommended during treatment.

Possible Side Effects

• Low blood pressure (hypotension).

• Dizziness and lightheadedness.

• Elevated blood potassium levels (hyperkalemia).

• Impaired kidney function.

• Cough.

• Fatigue and weakness.

• Headache.

• Nausea.

• Low blood sodium levels (hyponatremia) in some patients.

• Angioedema, a serious allergic-type reaction that may cause swelling of the face, lips, or tongue and difficulty breathing, requiring immediate medical attention.

Note: Entresto is a prescription medication used to treat heart failure and must be taken under the supervision of a qualified cardiologist. Treatment requires regular monitoring of blood pressure, kidney function, and potassium levels. The medication should not be discontinued, and the dosage should not be changed without consulting a physician.